U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07047586) titled 'Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab' on June 24.
Brief Summary: To evaluate the efficacy and safety of lenvatinib plus tislelizumab versus lenvatinib alone for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma (HCC)
Intervention:
DRUG: Tislelizumab
Tislelizumab will be administered by IV, 200 mg on day 1 of each 21 day cycle until documented...